First pill for rare bone disease enters human testing
NCT ID NCT07179640
Summary
This is the first study in people of an oral drug called ALE1 for hypophosphatasia (HPP), a rare genetic bone disorder. It aims to find out if the pill is safe, how the body processes it, and how it affects key biomarkers. The study will include about 120 healthy adults and adults with HPP, who will receive either the drug or a placebo.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HYPOPHOSPHATASIA (HPP) are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Fortrea Clinical Research Unit
RECRUITINGLeeds, United Kingdom
Contact Phone: •••-•••-••••
-
New Zealand Clinical Research
RECRUITINGGrafton, Auckland, 1010, New Zealand
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.